scispace - formally typeset
L

Lisheng Yang

Researcher at Xiamen University

Publications -  21
Citations -  438

Lisheng Yang is an academic researcher from Xiamen University. The author has contributed to research in topics: Epitope & Enterovirus 71. The author has an hindex of 12, co-authored 21 publications receiving 372 citations. Previous affiliations of Lisheng Yang include Enterprise Community Partners.

Papers
More filters
Journal ArticleDOI

The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children.

TL;DR: The results demonstrated broad cross-neutralizing activity induced by two C4 EV71 vaccines in healthy Chinese infants and children, however, the degree of induced cross-protective immunity, and the potential escape evolution for EV71 still need to be monitored and researched in future.
Journal ArticleDOI

Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop.

TL;DR: The results suggest that a broad-spectrum vaccine strategy targeting the high-affinity epitope of VP2 EF loop may elicits effective immune responses against EV71 infection.
Journal ArticleDOI

Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody.

TL;DR: The isolation of two forms of stable CVA6 particles-procapsid and A-particle-with excellent biochemical stability and natural antigenicity to serve as vaccine candidates are demonstrated and an immune-dominant neutralizing epitope is identified which can be exploited for vaccine development.
Journal ArticleDOI

A Broadly Cross-protective Vaccine Presenting the Neighboring Epitopes within the VP1 GH Loop and VP2 EF Loop of Enterovirus 71

TL;DR: It is illustrated that the chimeric VLP HBc-E1/2 is a promising candidate for a broad-spectrum HFMD vaccine, and also reveals mechanisms of protection by the neighboring linear epitopes of the VP1 GH and VP2 EF loops.
Journal ArticleDOI

Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay.

TL;DR: Antibodies induced by EV71-C4a were cross-reactive for different EV71 genotypes, demonstrating that C4a is a good candidate strain for an EV71 vaccine and that this new assay is practical for analyses of clinical samples from epidemiological and vaccine studies.